The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
Manufacturing Manufacture Of Chemicals And Pharamceuticals Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
1,400 jobs Number of planned job losses
Announcement Date
20 November 2008
Employment effect (start)
Foreseen end date
31 December 2013
Description
AstraZeneca, a Anglo-Swedish pharmaceutical company, has announced that it is to cut 1,400 jobs by 2013 and to close three European factories located in Belgium, Spain and Sweden. 250 job losses are also expected in the UK at the company's site in Macclesfield. Just over 1,050 of the job cuts will occur by 2010 with the remainder, mainly positions in Sweden, made between 2010 and 2013. A company's spokesman said that "these moves are a continuation of AstraZeneca's programme to improve the organisation's productivity and efficiency".
Eurofound (2008), Astra Zeneca, Internal restructuring in European Union, factsheet number 68046, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/68046.
Digitisation and automation technologies, including artificial intelligence (AI), can affect working conditions in a variety of ways and their use in the workplace raises a host of new ethical concerns.
The retail banking sector is fertile ground for studying the impacts of digitalisation on work and employment. Financial services are increasingly provided online, without the intermediary of customer-facing institutions.
European labour markets have recovered strongly from COVID-19. By the end of 2021, little more than 18 months after the start of the pandemic, employment rates in the EU were almost at pre-crisis levels.
